A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood
A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood
Rheumatoid arthritis is a systemic disease, it is not clear whether the gene expression
 profile exhibited by circulated peripheral blood cells and that expressed by the inflamed
 synovium mirror one another. Understanding this relationship would be useful not only in
 potentially having a relatively non-invasive means to predict response to therapy but it
 might be useful in better understanding differences in RA expression amongst patients with
 this disease, thus perhaps assisting in target identification through a better understanding
 of disease processes.
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease affecting approximately
 1% of the adult population. The disease is characterised by inflammation of synovial tissue
 (ST) in multiple joints, which often leads to destruction of joint integrity, contributing to
 serious functional impairment and disability. The contributors to its pathology include joint
 inflammation, abnormal cellular and humoral responses, and synovial hyperplasia.
 Ultrasonography is a powerful, non-invasive, and feasible way to evaluate synovial
 hyperplasia and guide its collection by biopsy.
Inclusion criteria

 -  Adult men and non-pregnant, non-lactating women between 18 and 75 years of age.
 Sexually active females must be of either non-childbearing potential or willing to
 comply with the contraceptive requirements

 -  Body weight greater >40 kg and <120 kg with a body mass index (BMI) between 19-31
 kg/m2

 -  Clinical history of rheumatoid arthritis as defined by ACR criteria

 -  Negative urine pregnancy test for women of child bearing age (except those with
 documented proof of hysterectomy or bilateral oophorectomy)

 For populations B and C only

 -  Currently on a stable dosing regimen of methotrexate 7.5 to 25 mg once weekly, as
 their only DMARD (no changes in dosing regimen for 4 weeks prior to screening).

 Exclusion criteria

 -  History of an acute illness within 2 weeks prior to the study

 -  History of drug abuse within 2 years

 -  Donation of blood in excess of 500 mL within 56 days prior to the first dose of study
 medication

 For group A only

 -  Prior treatment with disease modifying anti-rheumatic agents or biologicals.